STOCK TITAN
  1. Home
  2. News
  3. IMMX

Immix Biopharma Inc - IMMX STOCK NEWS

IMPACT
SENTIMENT
IMMX : Nasdaq
Immix Biopharma Announces Complete Response in 9th Relapsed/Refractory AL Amyloidosis Patient in NXC-201 Clinical Trial at IMS 20th Annual Meeting
clinical trial
IMPACT
SENTIMENT
IMMX : Nasdaq
Immix Biopharma Announces 72-Patient NXC-201 Clinical Data at the IMS 20th Annual Meeting, 95% Overall Response Rate in Multiple Myeloma
clinical trial
IMPACT
SENTIMENT
IMMX : Nasdaq
U.S. Food and Drug Administration Approves Orphan Drug Designation for Immix Biopharma NXC-201 as a Treatment for Amyloid Light Chain (AL) Amyloidosis
clinical trial fda approval
IMPACT
SENTIMENT
IMMX : Nasdaq
Immix Biopharma Subsidiary Nexcella Completes 2nd NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing Site
IMPACT
SENTIMENT
IMMX : Nasdaq
Nexcella, Immix Biopharma Subsidiary, to Present at the Bank of America 2023 Healthcare Trailblazers Private Company Conference
conferences
IMPACT
SENTIMENT
IMMX : Nasdaq
Immix Biopharma Announces Dr. Suzanne Lentzsch, Director of the Multiple Myeloma and Amyloidosis Program at the College of Physicians and Surgeons of Columbia University and at New York Presbyterian Hospital in New York, Joins Scientific Advisory Board
management
IMPACT
SENTIMENT
IMMX : Nasdaq
U.S. Food and Drug Administration Approves Orphan Drug Designation for Immix Biopharma NXC-201 as a Treatment for Multiple Myeloma
clinical trial fda approval
IMPACT
SENTIMENT
IMMX : Nasdaq
Immix Biopharma Announces Dr. Heather Landau, Memorial Sloan Kettering Cancer Center Amyloidosis Program Director, Joins Nexcella Scientific Advisory Board
management
IMPACT
SENTIMENT
IMMX : Nasdaq
Immix Biopharma Announces Additional NXC-201 AL Amyloidosis Clinical Data Accepted for Oral Presentation at the 20th International Myeloma Society Annual Meeting (September 27-30, Athens Greece)
clinical trial
IMPACT
SENTIMENT
IMMX : Nasdaq
Immix Biopharma Subsidiary Nexcella Announces NXC-201 Multiple Myeloma Clinical Data Abstract Accepted for Presentation at the 20th International Myeloma Society Annual Meeting
clinical trial
Stock IMMX logo
Immix Biopharma Inc
Nasdaq:IMMX

IMMX Stock Data

Pharmaceutical Preparation Manufacturing
Manufacturing